Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule

被引:46
作者
Somiya, Masaharu [1 ,2 ,3 ]
Kuroda, Shun'ichi [1 ,2 ]
机构
[1] Osaka Univ, Inst Sci & Ind Res, Ibaraki, Osaka 5670047, Japan
[2] Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan
[3] Japan Soc Promot Sci, Tokyo 1020083, Japan
关键词
Active targeting; Biomimicking; Hepatitis B virus; Liposome; Membrane fusion; Virus-like particle; HEPATITIS-B-VIRUS; L-PROTEIN PARTICLES; IN-VIVO; INTRACELLULAR TRAFFICKING; CAPSID PROTEINS; GENE-REGULATION; SIRNA; NANOPARTICLES; LIPOSOMES; CELLS;
D O I
10.1016/j.addr.2015.10.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As drug delivery systems, nanocarriers should be capable of executing the following functions: evasion of the host immune system, targeting to the diseased site, entering cells, escaping from endosomes, and releasing payloads into the cytoplasm. Since viruses perform some or all of these functions, they are considered naturally occurring nanocarriers. To achieve biomimicry of the hepatitis B virus (HBV), we generated the "bio-nanocapsule" (BNC)-which deploys the human hepatocyte-targeting domain, fusogenic domain, and polymerized-albumin receptor domain of HBV envelope L protein on its surface-by overexpressing the L protein in yeast cells. BNCs are capable of delivering various payloads to the cytoplasm of human hepatic cells specifically in vivo, which is achieved via formation of complexes with various materials (e.g., drugs, nucleic acids, and proteins) by electroporation, fusion with liposomes, or chemical modification. In this review, we describe BNC-related technology, discuss retargeting strategies for BNCs, and outline other virus-inspired nanocarriers. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:77 / 89
页数:13
相关论文
共 111 条
  • [11] Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071
  • [12] Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
    Davis, Mark E.
    Zuckerman, Jonathan E.
    Choi, Chung Hang J.
    Seligson, David
    Tolcher, Anthony
    Alabi, Christopher A.
    Yen, Yun
    Heidel, Jeremy D.
    Ribas, Antoni
    [J]. NATURE, 2010, 464 (7291) : 1067 - U140
  • [13] Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2
    Deshane, J
    Garner, CC
    Sontheimer, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (06) : 4135 - 4144
  • [14] In vitro reconstitution of SV40 particles that are composed of VP1/2/3 capsid proteins and nucleosomal DNA and direct efficient gene transfer
    Enomoto, Teruya
    Kukimoto, Iwao
    Kawano, Masa-aki
    Yamaguchi, Yuki
    Berk, Arnold J.
    Handa, Hiroshi
    [J]. VIROLOGY, 2011, 420 (01) : 1 - 9
  • [15] Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
    Felnerova, D
    Viret, JF
    Glück, R
    Moser, C
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2004, 15 (06) : 518 - 529
  • [16] GABIZON A, 1994, CANCER RES, V54, P987
  • [17] Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors
    Germershaus, Oliver
    Merdan, Thomas
    Bakowsky, Udo
    Behe, Martin
    Kissel, Thomas
    [J]. BIOCONJUGATE CHEMISTRY, 2006, 17 (05) : 1190 - 1199
  • [18] IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA-VIRUS VIROSOME VACCINE DELIVERY SYSTEM FOR IMMUNIZATION AGAINST HEPATITIS-A
    GLUCK, R
    MISCHLER, R
    BRANTSCHEN, S
    JUST, M
    ALTHAUS, B
    CRYZ, SJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) : 2491 - 2495
  • [19] Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems
    Hama, S
    Akita, H
    Ito, R
    Mizuguchi, H
    Hayakawa, T
    Harashima, H
    [J]. MOLECULAR THERAPY, 2006, 13 (04) : 786 - 794
  • [20] Hamada Hiroki, 2013, Clin Med Insights Womens Health, V6, P71, DOI 10.4137/CMWH.S8213